Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global current systems in the magnetosphere of Mercury.

Nature communications·2026
Same author

Response: Codeine in Breast Milk: Minimal Transfer, Still Risky for Neonates.

Paediatric anaesthesia·2026
Same author

Codeine and Metabolite Concentrations in the Breastfed Neonate.

Paediatric anaesthesia·2026
Same author

Milk Fasting Times and Aspiration in Infants.

Paediatric anaesthesia·2026
Same author

Whole blood transcriptomics reveals sepsis mortality-associated changes in neutrophil degranulation.

American journal of respiratory cell and molecular biology·2026
Same author

Individualising drug therapy in intensive care.

Anaesthesia and intensive care·2026
Same journal

Inflammatory Indices and Pediatric Emergence Delirium: Predictive Signal or Statistical Artifact?

Paediatric anaesthesia·2026
Same journal

Perspectives in Pediatric Ambulatory Anesthesia: Part 1-One Center's 15 Year Evolution in Eligibility, Utilization, Efficiency, and Outcomes.

Paediatric anaesthesia·2026
Same journal

Retrospective Evaluation of an Artificial Intelligence-Assisted Video Laryngoscope System for Tracheal Intubation in Infants and Neonates.

Paediatric anaesthesia·2026
Same journal

Perspectives in Pediatric Ambulatory Anesthesia: Part 2-One Center's 15 Year Experience Improving Quality and Safety Outcomes.

Paediatric anaesthesia·2026
Same journal

Response to: Reliability of the Pediatric Specific ASA Physical Status Classification.

Paediatric anaesthesia·2026
Same journal

Perspectives in Pediatric Ambulatory Anesthesia: Part 4-Evolving Solutions in Pediatric Ambulatory Anesthesia: From Registries to a Learning Health System Approach.

Paediatric anaesthesia·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Data sharing for pharmacokinetic studies.

Brian J Anderson1, Alan F Merry

  • 1Department of Anaesthesiology, University of Auckland, Auckland, New Zealand. briana@adhb.govt.nz

Paediatric Anaesthesia
|June 30, 2009
PubMed
Summary
This summary is machine-generated.

Sharing pediatric pharmacokinetic data enhances drug understanding for children

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Related Experiment Videos

Last Updated: Jun 22, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Area of Science:

  • Pharmacokinetics
  • Pediatric Pharmacology
  • Data Science

Background:

  • Data sharing in scientific research is increasingly common.
  • Pooling pediatric pharmacokinetic data offers robust analysis.
  • Challenges exist in data sharing practices.

Purpose of the Study:

  • To explore the benefits and challenges of data sharing in pediatric pharmacokinetic studies.
  • To advocate for data sharing to improve drug understanding and clinical benefit for children.
  • To address the ethical and practical considerations of data ownership and usage.

Main Methods:

  • Review of current data sharing practices in pediatric research.
  • Analysis of ethical and philosophical arguments surrounding data ownership.
  • Identification of barriers and facilitators to data sharing.

Main Results:

  • Data sharing enables robust pharmacokinetic analysis, covariate analysis, and hypothesis testing.
  • Benefits include result verification, cost/time savings, new interpretations, and educational value.
  • Reluctance to share stems from fear of data misuse, intellectual property concerns, and lack of clear guidelines.

Conclusions:

  • Establishing clear rules and consensus on data sharing processes is crucial for pediatric pharmacokinetic studies.
  • Collaboration and cooperation are essential for developing effective data-sharing frameworks.
  • Addressing concerns over data ownership and potential misuse will foster greater participation in data sharing initiatives.